Perrigo Yönetim

Yönetim kriter kontrolleri 2/4

Perrigo CEO'su Patrick Lockwood-Taylor, Jun2023 tarihinde atandı, in görev süresi 1.42 yıldır. in toplam yıllık tazminatı $ 6.67M olup, şirket hissesi ve opsiyonları dahil olmak üzere 9.1% maaş ve 90.9% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.033% ine doğrudan sahiptir ve bu hisseler $ 1.22M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.5 yıl ve 5.9 yıldır.

Anahtar bilgiler

Patrick Lockwood-Taylor

İcra Kurulu Başkanı

US$6.7m

Toplam tazminat

CEO maaş yüzdesi	9.1%
CEO görev süresi	1.4yrs
CEO sahipliği	0.03%
Yönetim ortalama görev süresi	2.5yrs
Yönetim Kurulu ortalama görev süresi	5.9yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Patrick Lockwood-Taylor'un ücretlendirmesi Perrigo'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 28 2024	n/a	n/a	-US$147m
Jun 29 2024	n/a	n/a	-US$114m
Mar 30 2024	n/a	n/a	US$800k
Dec 31 2023	US$7m	US$605k	-US$4m

Tazminat ve Piyasa: Patrick 'nin toplam tazminatı ($USD 6.67M ), UK pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 2.63M ).

Tazminat ve Kazançlar: Patrick şirketinin tazminatını şirket performansıyla karşılaştırmak için yeterli veri yok.

CEO

Patrick Lockwood-Taylor

1.4yrs

Görev süresi

US$6,672,584

Tazminat

Mr. Patrick Lockwood-Taylor has been President, Chief Executive Officer and Director at Perrigo Company plc since June 30, 2023. He had been Regional President and Head North American Consumer Health Busin...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Patrick Lockwood-Taylor	President	1.4yrs	US$6.67m	0.033% $ 1.2m
Eduardo Bezerra	Executive VP & CFO	2.5yrs	US$3.05m	0.011% $ 416.3k
Ronald Janish	Chief Transformation Officer and Executive VP of Global Operations & Supply Chain	9.1yrs	US$2.23m	0.019% $ 688.5k
Svend Andersen	Advisor	7.8yrs	US$2.55m	0.059% $ 2.2m
Kyle Hanson	Advisor	less than a year	US$2.28m	0.0082% $ 299.8k
Shannon Hukill	Senior Director of Technical Operations	13.2yrs	Veri yok	Veri yok
Alison Ives	Executive VP & Chief Scientific Officer	2.4yrs	Veri yok	0.014% $ 496.7k
Bradley Joseph	Vice President of Global Investor Relations & Corporate Communications	no data	Veri yok	Veri yok
Charles Atkinson	Executive VP	less than a year	Veri yok	Veri yok
Mary Reilly-Brest	Director of Global Organizational and Human Resource Development	16.8yrs	Veri yok	Veri yok
Robert Willis	Chief Human Resources Officer & Executive VP	5.7yrs	Veri yok	0.023% $ 847.6k
Catherine C. Schmelter	Executive VP and President of Consumer Self-Care Americas & Global Portfolio Optimization	1.2yrs	Veri yok	0.0019% $ 69.4k

2.5yrs

Ortalama Görev Süresi

55yo

Ortalama Yaş

Deneyimli Yönetim: 0Y5E 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.5 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Patrick Lockwood-Taylor	President	1.4yrs	US$6.67m	0.033% $ 1.2m
Jeffrey Kindler	Independent Director	7.8yrs	US$399.99k	0.017% $ 619.4k
Donal O'Connor	Independent Director	10yrs	US$405.30k	0.020% $ 718.6k
Bradley Alford	Independent Director	7.8yrs	US$387.49k	0.026% $ 969.6k
Albert Manzone	Independent Director	2.3yrs	US$387.49k	0.0054% $ 199.5k
Orlando Ashford	Independent Chairman of the Board	3.9yrs	US$532.99k	0.012% $ 423.6k
Julia Brown	Director	less than a year	US$12.53k	Veri yok
Geoffrey Parker	Independent Director	8yrs	US$387.49k	0.038% $ 1.4m
Adriana Karaboutis	Independent Director	7.5yrs	US$390.99k	0.016% $ 605.5k
Katherine Doyle	Independent Director	4.3yrs	US$392.80k	0.0044% $ 161.7k

5.9yrs

Ortalama Görev Süresi

60yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 0Y5E 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.9 yıldır).

Perrigo Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Perrigo Company plc Appoints Charles Atkinson, as Executive Vice President, General Counsel and Secretary

Advisor recently sold US$969k worth of stock

Perrigo Company plc Appoints David Ball as Executive Vice President and Chief Brand and Digital Officer

Perrigo Company plc Appoints Todd Penegor as Member of Board and to Serve on Audit Committee, Effective June 21, 2024

Perrigo Company plc Announces Executive Changes

Perrigo Company plc, Annual General Meeting, May 02, 2024

Recent updates

Third quarter dividend of US$0.28 announced

Third quarter 2024 earnings released: US$0.13 loss per share (vs US$0.11 profit in 3Q 2023)

Perrigo Company plc Provides Revenue Guidance for the Fiscal Year 2024

Perrigo Company plc Announces Quarterly Dividend, Payable on December 17, 2024

Perrigo Company plc to Report Q3, 2024 Results on Nov 06, 2024

Perrigo Company plc Appoints Charles Atkinson, as Executive Vice President, General Counsel and Secretary

Upcoming dividend of US$0.28 per share

Advisor recently sold US$969k worth of stock

Perrigo Company plc Appoints David Ball as Executive Vice President and Chief Brand and Digital Officer

Second quarter dividend of US$0.28 announced

Second quarter 2024 earnings released: US$0.77 loss per share (vs US$0.066 profit in 2Q 2023)

Perrigo Company plc Reports Impairment Charges for the Second Quarter Ended June 29, 2024

Perrigo Company plc to Report Q2, 2024 Results on Aug 02, 2024

Esteve Healthcare S.L. completed the acquisition of HRA Pharma Rare Diseases America, LLC from Perrigo Company plc.

Perrigo Company plc Appoints Todd Penegor as Member of Board and to Serve on Audit Committee, Effective June 21, 2024

Perrigo Company plc Announces Executive Changes

Upcoming dividend of US$0.28 per share

Perrigo Company plc Reaffirms Earnings Guidance for 2024

New major risk - Financial position

First quarter 2024 earnings released: EPS: US$0.03 (vs US$0.008 loss in 1Q 2023)

Fourth quarter dividend of US$0.28 announced

Perrigo Company plc Announces Quarterly Dividend, Payable on June 18, 2024

Esteve Healthcare S.L. agreed to acquire HRA Pharma Rare Diseases America, LLC from Perrigo Company plc (NYSE:PRGO) for approximately €280 million.

Perrigo Company plc to Report Q1, 2024 Results on May 07, 2024

Perrigo Company plc, Annual General Meeting, May 02, 2024

Perrigo Company plc Announces Erica L. Mann Not to Stand for Re-Election to its Board of Directors

Fourth quarter dividend increased to US$0.28

Perrigo Company plc Reports Impairment Charges for the Fourth Quarter Ended December 31, 2023

Perrigo Company plc Reports Earnings Guidance for the Fiscal Year 2024

Full year 2023 earnings released: US$0.033 loss per share (vs US$0.97 loss in FY 2022)

Perrigo Company plc Increases its Quarterly Dividend, Payable on March 26, 2024

Perrigo Company plc to Report Q4, 2023 Results on Feb 27, 2024

Upcoming dividend of US$0.27 per share at 3.6% yield

Perrigo Company plc Updates Earnings Guidance for the Fiscal 2023

Perrigo Company plc to Report Q3, 2023 Results on Nov 07, 2023

Perrigo Company plc Announces Executive Changes

Perrigo Company plc Reaffirms Earnings Guidance for the Fiscal 2023

Perrigo Company plc to Report Q2, 2023 Results on Aug 08, 2023

Perrigo Company plc Announces U.S. FDA Approval for Opill OTC Daily Oral Contraceptive

Perrigo Company plc Appoints Patrick Lockwood-Taylor as Its New Chief Executive Officer

Perrigo Announces U.S. FDA Approval for Nicotine Coated Mint Lozenge

Perrigo Company plc Announces FDA Approval of Opill®? for Over-The-Counter Use

Perrigo Company plc Reaffirms Sales Guidance for the Fiscal Year 2023

Perrigo Announces Quarterly Dividend, Payable on June 20, 2023

Perrigo Company plc to Report Q4, 2022 Results on Feb 27, 2023

Theodore R. Samuels Not to Stand for Re-Election to the Perrigo Company plc's Board of Directors

Perrigo Company plc Provides Earnings Guidance for the Fiscal Year 2022

Perrigo Company plc Announces Quarterly Dividend, Payable on December 20, 2022

Perrigo Company plc (NYSE:PRGO) acquired Good Start Packaging, Inc. from Nestle Canada Inc.

Perrigo Company plc to Report Q3, 2022 Results on Nov 08, 2022

Perrigo Company plc Announces Litigation Update

Perrigo Company Revised Earnings Guidance for the Full Year of 2022

Perrigo Company plc Declares Quarterly Dividend, Payable on September 20, 2022

Perrigo Company plc to Report Q2, 2022 Results on Aug 09, 2022

Perrigo Company plc Appoints Albert A. Manzone to Serve as A Member of the Board of Directors and Member of the Talent & Compensation Committee, to Be Effective July 30, 2022

Perrigo Company plc Promotes Alison Ives to Executive Vice President and Chief Scientific Officer

Perrigo Company plc Announces U.S. FDA Approval for Omeprazole Magnesium Delayed-Release Mini Capsules

Perrigo Company plc Announces Retirement of Todd Kingma as Executive Vice President, General Counsel, and Corporate Secretary, Effective August 31, 2022

Perrigo Company plc Raises Earnings Guidance for the Fiscal Year 2022

Perrigo Company plc Declares Quarterly Dividend, Payable on June 21, 2022

Perrigo Company plc Provides Earnings Guidance for the Year 2022

Perrigo Company plc Announces Quarterly Dividend, Payable on March 17, 2022

Perrigo Company plc to Report Q4, 2021 Results on Mar 01, 2022

Perrigo Company plc(TASE:PRGO) dropped from TA-35 Index

Perrigo Announces Voluntary Delisting from the Tel Aviv Stock Exchange

Third quarter 2021 earnings released: US$0.40 loss per share (vs US$1.13 loss in 3Q 2020)

Perrigo Company plc (NYSE:PRGO) signed a binding offer to acquire HRA Pharma, SA from funds affiliated with Astorg Partners and Goldman Sachs Asset Management, L.P. for transaction value of €1.8 billion.

Upcoming dividend of US$0.24 per share

Second quarter 2021 earnings released: US$0.84 loss per share (vs US$0.44 profit in 2Q 2020)